EXHIBIT 4.15
ADVANCED VIRAL RESEARCH CORP.
SECURITIES PURCHASE AGREEMENT
WARRANTS TO PURCHASE
SHARES OF COMMON STOCK, PAR VALUE $.00001 PER SHARE
PURCHASE AGREEMENT
DATED June 23, 1999
TABLE OF CONTENTS
ARTICLE 1. AUTHORIZATION OF THE SECURITIES.................................................................1
ARTICLE 2. SALE AND PURCHASE OF THE SECURITIES; CLOSING....................................................1
2.1. Sale and Purchase the Securities................................................................1
2.2. Closing.........................................................................................1
ARTICLE 3. PURCHASERS' REPRESENTATIONS AND WARRANTIES......................................................2
3.1. Qualified Buyer.................................................................................2
3.2. Compliance With Laws............................................................................2
3.3. Qualified Investor Questionnaire................................................................2
3.4. Capacity to Enter into Agreement................................................................2
3.5. Ownership in the Company........................................................................3
3.6. Independent Investigation.......................................................................3
3.7. No Government Recommendation or Approval........................................................3
3.8. Further Limitations on Disposition..............................................................3
3.9. Legal Representation............................................................................3
3.10 Separate Purchasers.............................................................................3
ARTICLE 4. REPRESENTATIONS AND WARRANTIES OF THE COMPANY...................................................4
4.1. Organization and Existence, etc.................................................................4
4.2. Subsidiaries and Affiliates.....................................................................4
4.3. Capitalization..................................................................................4
4.4. Authorization...................................................................................5
4.5. Binding Obligations: No Material Adverse Contracts, etc.........................................5
4.6. Compliance with Instruments, etc................................................................5
4.7. Litigation......................................................................................5
4.8. Offering........................................................................................5
4.9. Permits: Governmental and Other Approvals.......................................................5
4.10. SEC Reports.....................................................................................6
4.11. Copyrights, Trademarks and Patents..............................................................6
4.12. Other Material Contracts........................................................................6
4.13. Disclosure......................................................................................6
ARTICLE V CONDITIONS TO PURCHASERS CLOSING.......................................................................7
5.1. Representations and Warranties Correct..........................................................7
5.2. Performance.....................................................................................7
5.3. No Impediments..................................................................................7
5.4. Other Agreements................................................................................7
5.5. Legal Investment................................................................................7
5.6. Due Diligence Investigation.....................................................................7
5.7. Proceedings and Other Documents.................................................................7
-i-
ARTICLE VI CONDITIONS TO CLOSING OF THE COMPANY..................................................................8
6.1. Representations.................................................................................8
6.2. Legal Investment................................................................................8
6.3. Payment of Purchase Price.......................................................................8
ARTICLE VII AFFIRMATIVE COVENANTS AND INDEMNITY .................................................................8
7.1. Further Assurances..............................................................................8
7.2. Registration Rights.............................................................................8
7.3. Indemnification.................................................................................9
ARTICLE VIII COMPLIANCE WITH THE SECURITIES ACT ................................................................10
8.1. Legends........................................................................................10
ARTICLE IX MISCELLANEOUS........................................................................................11
9.1. Governing Law..................................................................................11
9.2. Survival.......................................................................................11
9.3. Successors and Assigns.........................................................................11
9.4. Entire Agreement...............................................................................11
9.5. Amendment......................................................................................11
9.6. Notices, etc...................................................................................11
9.7. Delays or Omissions............................................................................12
9.8. Severability...................................................................................12
9.9. Placement Fee..................................................................................12
9.10. Expenses.......................................................................................12
9.11. Litigation.....................................................................................12
9.12. Titles and Subtitles...........................................................................13
9.13. Counterparts...................................................................................13
-ii-
June 23, 1999
AGREEMENT dated this 23 day of June, 1999 by and between ADVANCED VIRAL
RESEARCH CORP., a Delaware corporation (the "Company"), with offices at ▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇ and each of those persons,
severally and not jointly, listed as a purchaser on the Schedule of purchasers
attached as Exhibit B hereto. Such persons are hereafter collectively referred
to as the "Purchasers" and each individually as a "Purchaser".
ARTICLE 1.
AUTHORIZATION OF THE SECURITIES
-------------------------------
The Company represents that it has taken all corporate action necessary
to authorize the issuance and sale of 1,851,852 shares of Common Stock of the
Company, par value $.00001 per share ("Common Stock") and warrants to purchase
an aggregate of 925,926 shares of Common Stock of the Company (the "Warrants").
The Common Stock and the Warrants (collectively, the "Securities") are to be
sold to each Purchaser pursuant to this Agreement. For purposes of this
Agreement the term "Shares" shall mean the shares of Common Stock purchased
hereunder and the shares of Common Stock which may be issued from time to time
pursuant to the exercise of the Warrants.
ARTICLE 2.
SALE AND PURCHASE OF THE SECURITIES; CLOSING
--------------------------------------------
2.1. Sale and Purchase the Securities. Subject to the terms and
conditions hereof and in reliance on the representations and warranties
contained herein, or made pursuant hereto, the Company will issue and sell to
each Purchaser as more particularly referred to below, and each Purchaser will
purchase from the Company, on the Closing Date specified in Section 2.2, the
Securities for the purchase price set forth next to the name of such Purchaser
on Exhibit B, at an aggregate purchase price for all Purchasers of $500,000 (the
"Aggregate Purchase Price").
2.2. Closing.
(a) The closing of the purchase and sale of the Securities
(the "Closing") shall be deemed to occur when this Agreement has been executed
by both the Company and Purchaser and the Company has received payment for the
Securities. The date on which this occurs is herein called the "Closing Date."
(b) On the Closing Date there will be delivered to each
Purchaser (i) the shares of Common stock indicated on Exhibit B registered in
his name and (ii) warrant certificates in the forms of Exhibits A-1 and A-2
registered in such names representing the right to purchase the number of shares
of Common Stock set forth therein. The foregoing Securities shall be delivered
by the Company, against delivery by the Purchasers to the Company of an
unendorsed certified or official bank check drawn upon or issued by a bank which
is a member of the New York
1
Clearinghouse for banks (or wire transfer) for the aggregate purchase price to
be paid by such Purchaser) payable to the order of the Company.
ARTICLE 3.
PURCHASERS' REPRESENTATIONS AND WARRANTIES
------------------------------------------
Each Purchaser represents and warrants to and covenants with the
Company that:
3.1. Qualified Buyer. Purchaser is an "accredited investor" within the
meaning of Rule 501 of Regulation D promulgated under the Securities Act of
1933, as amended (the "Securities Act"). Either alone or together with the
advice of a representative, Purchaser is sophisticated and experienced in
making, and is qualified to make, decisions with respect to investments in
securities presenting an investment decision like that involved in the purchase
of the Securities, including investments in securities issued by the Company.
Purchaser has requested, received, reviewed and considered, either alone or with
a representative, all information Purchaser deems relevant in making an informed
decision to purchase the Securities.
3.2. Compliance With Laws. Purchaser will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to
buy, purchase or otherwise acquire or take a pledge of) any of the Securities
purchased hereunder except in compliance with the Securities Act, applicable
blue sky laws, and the rules and regulations promulgated thereunder.
3.3. Qualified Investor Questionnaire. Purchaser has completed or
caused to be completed the Confidential U.S. Purchaser Questionnaire For
Individuals, attached hereto as Appendix I. The answers thereto are true and
correct as of the date hereof and will be true and correct as of the Closing
(provided that Purchaser shall be entitled to update such information by
providing notice thereof to the Company prior to the Closing).
3.4. Capacity to Enter into Agreement. Purchaser has full right, power,
authority and capacity to enter into this Agreement and to consummate the
transactions contemplated hereby. Upon the execution and delivery of this
Agreement by Purchaser, this Agreement shall constitute a valid and binding
obligation, enforceable in accordance with its terms, except (a) as
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors' and contracting
parties' rights generally, and (b) as limited by equitable principles generally.
3.5. Ownership in the Company. Upon completion of the transaction or
upon exercise of any Warrant, Purchaser will not directly or beneficially own
more than 4.9% of the Common Stock of the Company.
3.6. Independent Investigation. In electing to purchase the Securities
hereunder, Purchaser has relied solely upon the representations and warranties
of the Company set forth in this Agreement and on independent investigation made
by Purchaser and his representatives, if any, and Purchaser has not been given
any oral or written representations or assurance from the Company or any
representative of the Company other than as set forth in this Agreement or in a
2
document executed by a duly authorized representative of the Company making
reference to this Agreement.
3.7. No Government Recommendation or Approval. Purchaser understands
that no United States federal or state agency, or similar agency of any other
country, has passed upon or made any recommendation or endorsement of the
Company, this transaction or the purchase of the Securities.
3.8. Further Limitations on Disposition. Without in any way limiting
the representations set forth above, Purchaser agrees not to make any
disposition of all or any portion of the Securities (or the Shares issuable upon
the exercise of the Warrants) unless and until (a) there is then in effect a
registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration
statement, or (b) the disposition is made pursuant to an available exemption
from the registration requirements of the Securities Act and in the case of
clause (b) Purchaser shall have furnished the Company with an opinion of
counsel, reasonably satisfactory to the Company, that such disposition will not
violate any of the securities laws of the United States.
3.9. Legal Representation. Purchaser has had the opportunity to be
represented in this transaction by counsel of his own choice and has been so
advised by counsel for the Company.
3.10 Separate Purchasers. Each Purchaser is a separate investor; no
Purchaser is acting in concert with any other Purchaser or any other person in
connection with the purchase of Securities pursuant to this Agreement.
ARTICLE 4.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
---------------------------------------------
Other than as provided in the Schedule of Exceptions attached hereto as
Exhibit C, the Company represents and warrants as follows:
4.1. Organization and Existence, etc. The Company is a corporation duly
organized and validly existing and in good standing under the laws of its
jurisdiction of incorporation, and has all requisite corporate power and
authority to carry on its business as now conducted and proposed to be
conducted; the Company has all requisite corporate power and authority to enter
into this Agreement, to issue the Securities as contemplated herein and to carry
out and perform its obligations under the terms and conditions of this
Agreement. The Company does not own or lease any property or engage in any
activity in any jurisdiction which might require qualification to do business as
a foreign corporation in such jurisdiction and where the failure to so qualify
would have a material adverse effect on the financial condition of the Company
or subject the Company to a material liability. To the extent the Company has
not qualified to do business in such jurisdictions, it has, as of the date
hereof, prepared the necessary applications or documents to be filed with the
appropriate authorities in such jurisdictions to obtain such qualifications. The
Company has furnished each Purchaser with true, correct and complete copies of
its Certificate of Incorporation, By-laws and all amendments thereto to date.
3
4.2. Subsidiaries and Affiliates. Except as set forth in the Schedule
of Exceptions, the Company has no subsidiaries and does not, and upon the
Closing will not, own of record or beneficially any capital stock or equity
interest or investment in any corporation, association or business entity.
4.3. Capitalization.
(a) As of the date hereof, the Company's authorized capital
stock consists of 1,000,000,000 shares of Common Stock, par value $.00001 per
share, of which 301,340,183 are outstanding and 58,567,337 of which are reserved
for issuance to certain persons (not including shares which may be reserved for
issuance upon conversion of a convertible debenture in the principal amount of
$2,000,000) for the purposes stated in the Schedule of Exceptions. As of the
date hereof, the Company does not hold any shares of its capital stock in its
treasury.
(b) All the issued and outstanding shares of capital stock of
the Company shall, as of the Closing, (i) have been duly authorized and validly
issued, (ii) be fully paid and nonassessable, and (iii) have been offered,
issued, sold and delivered by the Company in compliance with applicable federal
and state securities laws. Other than as set forth in Section 4.3(a) and the
Schedule of Exceptions, there are no outstanding preemptive, conversion or other
rights, options, warrants, calls, agreements or commitments granted or issued by
or binding upon the Company, for the purchase or acquisition of any shares of
its capital stock.
4.4. Authorization. All corporate action on the part of the Company and
the directors and stockholders of the Company necessary for the authorization,
execution, delivery and performance by the Company of this Agreement and the
transactions contemplated herein, and for the authorization, issuance and
delivery of the Securities, has been taken or will have been taken prior to the
Closing.
4.5. Binding Obligations: No Material Adverse Contracts, etc. This
Agreement is a valid and binding obligation of the Company enforceable in
accordance with its terms. The execution, delivery and performance by the
Company of this Agreement and compliance herewith will not result in any
violation of and will not conflict with, or result in a breach of any of the
terms of, or constitute a default under, any provision of state or Federal law
to which the Company is subject, the Certificate of Incorporation, as amended,
or the By-laws, as amended, of the Company, or any mortgage, indenture,
agreement, instrument, judgment, decree, order, rule or regulation or other
restriction to which the Company is a party or by which it is bound, or, result
in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of
the properties or assets of the Company pursuant to any such term. Except as set
forth herein no stockholder of the Company has or will have any preemptive
rights or rights of first refusal by reason of the issuance of the Securities.
4.6. Compliance with Instruments, etc. Except as set forth in the
Schedule of Exceptions, the Company is not (a) in default past any grace, notice
or cure period under any indenture, agreement or instrument to which it is a
party or by which it is bound, (b) in violation of its Certificate of
Incorporation, By-laws or of any applicable law, (c) in default with respect to
4
any order, writ, injunction or decree of any court, administrative agency or
arbitrator, or in default under any order, license, regulation or demand of any
government agency, which default or violation would materially and adversely
affect the business, properties, condition (financial or otherwise) or business
prospects of the Company.
4.7. Litigation. Except as set forth in the Schedule of Exceptions,
there is no action, suit or proceeding pending, or, to the knowledge of the
Company, threatened, against the Company before any court, administrative agency
or arbitrator or any action, suit or proceeding pending, or, to the knowledge of
the Company, threatened, which challenges the validity of any action taken or to
be taken pursuant to or in connection with this Agreement or the issuance of the
Securities.
4.8. Offering. Subject in part to the truth and accuracy of the
representations made by each Purchaser herein and such Purchaser's compliance
with his covenants set forth in this Agreement, the offer, sale and issuance of
the Securities as contemplated by this Agreement are not subject to the
registration requirements of the Securities Act, and the Company, or anyone
acting on its behalf, will not take any action hereafter that would cause such
registration requirements to be applicable.
4.9. Permits: Governmental and Other Approvals. The Company possesses
such franchises, licenses, permits and other authority as are necessary for the
conduct of its business as now being conducted and proposed to be conducted by
the Company and the Company is not in default under any of such franchises,
licenses, permits or other authority. No approval, consent, authorization or
other order of, and no designation, filing, registration, qualification or
recording with, any governmental authority or any other person or entity is
required in connection with the Company's valid execution, delivery and
performance of this Agreement or the offer, issuance and sale of the Securities
by the Company to Purchaser or the consummation of any other transaction
contemplated on the part of the Company hereby.
4.10. SEC Reports.
(a) The Company has filed with the Securities and Exchange
Commission (the "Commission") all reports ("SEC Reports") required to be filed
by it under the Securities Act of 1934, as amended (the "Exchange Act"). All of
the SEC Reports filed by the Company comply in all material respects with the
requirements of the Exchange Act. None of the SEC Reports contains as of the
respective dates thereof, any untrue statement of a material fact or omits to
state any material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances under which they
were made. All financial statements contained in the SEC Reports have been
prepared in accordance with generally accepted accounting principles
consistently applied throughout the period indicated ("GAAP"). Each balance
sheet presents fairly in accordance with GAAP the financial position of the
Company as of the date of such balance sheet, and each statement of operations,
of stockholders' equity and of cash flows presents fairly in accordance with
GAAP the results of operations, the stockholders' equity and the cash flows of
the Company for the periods then ended.
5
(b) No event has occurred since March 31, 1999 requiring the
filing of an SEC Report that has not heretofore been filed.
(c) The SEC Reports and this Agreement taken together as a
whole will not, as of the Closing Date, contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein,
or necessary to make the statements contained therein, in light of the
circumstances under which they were made, not misleading.
4.11. Copyrights, Trademarks and Patents. Set forth in the Schedule of
Exceptions is a list of all the copyrights, trademark registrations and patents
and applications therefor owned by the Company.
4.12. Other Material Contracts. Set forth in the Schedule of Exceptions
is a list of contracts material to the operations of the Company to which
reference is not made elsewhere in this Article IV.
4.13. Disclosure. The information heretofore provided and to be
provided pursuant to this Agreement, including the Schedule of Exceptions and
the Exhibits thereto, and each of the agreements, documents, certificates and
writings previously delivered to Purchaser or his representatives, do not and
will not contain any untrue statement of material fact and do not and will not
omit to state a material fact required to be stated herein or therein or
necessary in order to make the statements and writings contained herein and
therein not false or misleading in light of the circumstances under which they
were made .To the knowledge of the Company, there is no fact which materially
adversely affects the business, prospects or condition (financial or otherwise)
of the Company which has not been set forth herein.
ARTICLE V
CONDITIONS TO PURCHASERS CLOSING
--------------------------------
Each Purchaser's obligation to purchase the Securities at the
Closing is subject to the fulfillment to such Purchaser's satisfaction on or
prior to the Closing Date of each of the following conditions, any of which may
be waived by such Purchaser:
5.1. Representations and Warranties Correct. The representations and
warranties in Article IV hereof shall be true and correct in all material
respects when made, and shall be true and correct in all material respects on
the Closing Date with the same force and effect as if they had been made on and
as of the Closing Date.
5.2. Performance. All covenants, agreements and conditions contained
in this Agreement to be performed or complied with by the Company on or prior to
the Closing Date shall have been performed or complied with by the Company in
all material respects.
5.3. No Impediments. Neither Purchaser nor the Company shall be
subject to any order, decree or injunction of a court or administrative agency
of competent jurisdiction
6
which would impose any material limitation on Purchaser's ability to exercise
full rights of ownership of the Securities.
5.4. Other Agreements. The Company shall have issued to Purchaser all
of the Securities.
5.5. Legal Investment. At the time of the Closing, the purchase of the
Securities to be purchased hereunder shall be legally permitted by all laws and
regulations to which Purchaser and the Company are subject.
5.6. Due Diligence Investigation. No Purchaser shall have discovered
any fact, whether or not reflected in the Schedule of Exceptions, which in such
Purchaser's determination would make the consummation of the transactions
contemplated by this Agreement not in his best interests.
5.7. Proceedings and Other Documents. All corporate and other
proceedings in connection with the transactions contemplated by this Agreement
shall have been taken and Purchaser shall have received such other documents, in
form and substance reasonably satisfactory to Purchaser, as to such other
matters incident to the transaction contemplated hereby as Purchaser may
reasonably request.
ARTICLE VI
CONDITIONS TO CLOSING OF THE COMPANY
------------------------------------
The Company's obligation to sell the Securities at the Closing is
subject to the fulfillment to its satisfaction on or prior to the Closing Date
of each of the following conditions:
6.1. Representations. The representations made by each Purchaser in
Article III hereof shall be true and correct when made and shall be true and
correct on the Closing Date.
6.2. Legal Investment. At the time of the Closing, the offer, sale and
purchase of the Securities shall be legally permitted by all laws and
regulations to which the Purchasers and the Company are subject.
6.3. Payment of Purchase Price. The Company shall have received
payment in full of the Aggregate Purchase Price.
ARTICLE VII
AFFIRMATIVE COVENANTS AND INDEMNITY
-----------------------------------
The Purchasers and the Company hereby covenant and agree as follows:
7.1. Further Assurances. From time to time the Company shall execute
and deliver to each Purchaser and each Purchaser shall execute and deliver to
the Company such other instruments, certificates, agreements and documents and
take such other action and do all other
7
things as may be reasonably requested by the other party in order to implement
or effectuate the terms and provisions of this Agreement and any of the
Securities.
7.2. Registration Rights.
(a) The Company shall file a registration statement (the
"Registration Statement") with the Commission, on such form as the Company deems
to be appropriate, to register the Shares under the Securities Act. The Company
shall use its best efforts to cause the Registration Statement to be declared
effective by the Commission on or prior to the 150th day after the Closing (the
"Effective Deadline"). Notwithstanding any other provision contained herein, the
failure of the Company to cause the Registration Statement to be declared
effective by the Commission on or prior to the Effective Deadline shall not be
deemed an event of default under this Agreement which shall subject the Company
to any liability or obligation except as otherwise provided herein.
(b) In the event the Registration Statement is not declared
effective by the Commission prior to the Effective Deadline, the Company shall
pay each Purchaser a penalty equal to the sum of 2% of the "amount" next to each
Purchaser's name on Exhibit B for each full calendar month lapsed after the
Effective Deadline, and a pro rated amount of said 2% based on a month of 30 or
31 days (as applicable to the month in which the Registration Statement is
declared effective). In no event shall the aggregate amount payable as a penalty
hereunder exceed $20,000 for all Purchasers.
(c) Purchaser shall furnish to the Company such information as
the Company shall reasonably request in writing and as shall be required in
connection with the registration.
7.3. Indemnification.
(a) The Company agrees to indemnify and hold each Purchaser
harmless from and against any losses, claims, damages or liabilities to which
such Purchaser may become subject (under the Securities Act or otherwise)
insofar as such losses, claims, damages or liabilities (or actions or
proceedings in respect thereof) arise out of, or are based upon, any Untrue
Statement (as defined below) on or after the effective date of the Registration
Statement, or arise out of any failure by the Company to fulfill any undertaking
included in the Registration Statement and the Company will reimburse such
Purchaser any reasonable legal or other expenses reasonably incurred in
investigating, defending or preparing to defend any such action, proceeding or
claim; provided, however, that the Company shall not be liable in any such case
to the extent that such loss, claim, damage or liability arises out of, or is
based upon, an Untrue Statement made in such Registration Statement in reliance
upon and in conformity with written information furnished to the Company by such
Purchaser or on such Purchaser's behalf, specifically for use in preparation of
the Registration Statement, or any statement or omission in any prospectus that
is corrected in any subsequent prospectus that was delivered prior to the
pertinent sale or sales by such Purchaser of his Shares.
8
(b) Each Purchaser agrees to indemnify and hold harmless the
Company and each person, if any, who controls the Company within the meeting of
Section 15 of the Securities Act, each officer of the Company who signs the
Registration Statement and each director of the Company from and against any
losses, claims, damages or liabilities to which the Company or any such officer,
director or controlling person may become subject (under the Securities Act or
otherwise), insofar as such losses, claims, damages or liabilities (or actions
or proceedings in respect thereof) arise out of, or are based upon, any failure
to comply with such Purchaser's representation and warranties hereunder, or any
Untrue Statement contained in the Registration Statement on or after the
effective date thereof if such Untrue Statement was made in reliance upon and in
conformity with written information furnished by such Purchaser or on such
Purchaser's behalf specifically for use in preparation of the Registration
Statement, as the case may be, for any legal or other expenses reasonably
incurred in investigating, defending or preparing to defend any such action,
proceeding or claim; provided, however, that in no event shall such Purchaser's
indemnity exceed the gross proceeds received by Purchaser from the sale of
Shares covered by such Registration Statement.
(c) Promptly after receipt by any indemnified person of a
notice of a claim or the beginning of any action in respect of which indemnity
is to be sought against an indemnifying person pursuant to this section, such
indemnified person shall notify the indemnifying person in writing of such claim
or of the commencement of such action, and, subject to the provisions
hereinafter stated, in case any such action shall be brought against an
indemnified person and such indemnifying person shall have been notified
thereof, such indemnifying person shall be entitled to participate therein, and,
to the extent it shall wish, to assume the defense thereof, with counsel
reasonably satisfactory to such indemnified person. After notice from the
indemnifying person to such indemnified person of its election to assume the
defense thereof, such indemnifying person shall not be liable to such
indemnified person for any legal expenses subsequently incurred by such
indemnified person in connection with the defense thereof; provided, however,
that if there exists or shall exist a conflict of interest that would make it
inappropriate, in the opinion of counsel to the indemnified person, for the same
counsel to represent both the indemnified person and such indemnifying person or
any affiliate or associate thereof, the indemnified person shall be entitled to
retain its own counsel at the expense of such indemnifying person; provided
further, however, that no indemnifying person shall be responsible for the fees
and expenses of more than one separate counsel for all indemnified parties.
(d) "Untrue Statement" means any untrue statement or alleged
untrue statement, or any omission or alleged omission to state in the
Registration Statement a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.
9
ARTICLE VIII
COMPLIANCE WITH THE SECURITIES ACT
----------------------------------
8.1. Legends. The certificate(s)representing the Securities delivered
to the Purchasers at Closing shall be stamped or otherwise imprinted with a
legend substantially similar the following ( in addition to any other legend
required under applicable state securities laws):
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER
THE ACT OR, IN THE OPINION OF COUNSEL OR BASED ON OTHER WRITTEN EVIDENCE IN THE
FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER,
SALE OR TRANSFER, PLEDGE, OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
ARTICLE IX
MISCELLANEOUS
-------------
9.1. Governing Law. This Agreement and the rights of the parties
hereunder shall be governed in all respects by the laws of the State of New
York.
9.2. Survival. The representations, warranties, covenants and
agreements made herein shall survive the Closing, for a period of one year from
the date of Closing.
9.3. Successors and Assigns. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding upon
and enforceable by and against, the successors, assigns, heirs, executors and
administrators of the parties hereto; provided, however, that the Company may
not assign its rights hereunder.
9.4. Entire Agreement. This Agreement (including the Exhibits hereto)
and the other documents delivered pursuant hereto and simultaneously herewith
constitute the full and entire understanding and agreement between the parties
with regard to the subject matter hereof and thereof.
9.5. Amendment. This Agreement may not be amended, discharged or
terminated without the written consent of each Purchaser and that of the
Company.
9.6. Notices, etc. All notices, demands or other communications given
hereunder shall be in writing and shall be sufficiently given if delivered
either personally or by a nationally recognized courier service marked for next
business day delivery or sent in a sealed envelope by first class mail, postage
prepaid and either registered or certified, addressed as follows:
10
(a) if to the Company:
Advanced Viral Research Corp.
▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, M.D.
President and Chief Executive Officer
(b) if to Purchaser, to the address set forth on Exhibit B to
this Agreement or to such other address with respect to any party hereto as such
party may from time to time notify (as provided above) the other parties hereto.
Any such notice, demand or communication shall be deemed to have been given (i)
on the date of delivery, if delivered personally, (ii) one business day after
delivery to a nationally recognized overnight courier service, if marked for
next day delivery or (iii) five business days after the date of mailing, if
mailed.
Copies of any notice, demand or communication given to the Company
shall be delivered to Wolf, Block, ▇▇▇▇▇▇ and ▇▇▇▇▇-▇▇▇▇▇ LLP, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇,
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇▇▇, Attn.: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Esq., or such other address
as may be directed.
9.7. Delays or Omissions. No delay or omission to exercise any right,
power or remedy accruing to any holder of any Securities upon any breach or
default of the Company under this Agreement shall impair any such right, power
or remedy of such holder nor shall it be construed to be a waiver of any such
breach or default, or an acquiescence, therein, or of or in any similar breach
or default thereafter occurring; nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. Any waiver, permit, consent or approval of any kind or
character on the part of any holder of any breach or default under this
Agreement, or any waiver on the part of any holder of any provisions or
conditions of this Agreement must be made in writing and shall be effective only
to the extent specifically set forth in such writing. Except as otherwise
provided herein, all remedies, either under this Agreement or by law or
otherwise afforded to any holder, shall be cumulative and not alternative.
9.8. Severability. In case any provision of this Agreement shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.
9.9. Placement Fee. Each Purchaser hereby represents and warrants to
the Company that he has not retained a finder or broker in connection with the
transactions contemplated by this Agreement. The Company hereby represents and
warrants to each Purchaser that it has not retained a finder or broker in
connection with the transactions contemplated by this Agreement. The Company
agrees to indemnify and to hold each Purchaser harmless of and from any
liability for commission or compensation in the nature of an agent's or broker's
fee to any broker, person or firm claiming to have been retained by the Company
to act as a finder or broker in connection
11
with this transaction and the costs and expenses of defending against such
liability or asserted liability. Each Purchaser agrees to indemnify and to hold
the Company harmless of and from any liability for commission or compensation in
the nature of an agent's or broker's fee to any broker, person or firm claiming
to have been retained by or on behalf of such Purchaser to act as a finder or
broker in connection with this transaction and the costs and expenses of
defending against such liability or asserted liability. The provisions of
Article 7.3(c) shall apply to any indemnification under this Section 9.9.
9.10. Expenses. Each of the parties shall bear its own expenses and
legal fees incurred on its behalf with respect to the negotiation, execution and
consummation of the transactions contemplated by this Agreement.
9.11. Litigation. The parties each hereby waive trial by jury in any
action or proceeding of any kind or nature in any court in which an action may
be commenced arising out of this Agreement or by reason of any other cause or
dispute whatsoever between them. The parties hereto agree that the State and
Federal Courts which sit in the State of New York and the County of New York
shall have exclusive jurisdiction to hear and determine any claims or disputes
between the Company and such holders, pertaining directly or indirectly to this
Agreement or to any matter arising therefrom. The parties each expressly submit
and consent in advance to such jurisdiction in any action or proceeding
commenced in such courts provided that such consent shall not be deemed to be a
waiver of personal service of the summons and complaint, or other process or
papers issued therein. The choice of forum set forth in this Section 9.11 shall
not be deemed to preclude the enforcement of any judgment obtained in such forum
or the taking of any action under this Agreement to enforce same in any
appropriate jurisdiction. The parties each waive any objection based upon forum
non conveniens and any objection to venue of any action instituted hereunder.
9.12. Titles and Subtitles. The titles of the articles, sections and
subsections of this Agreement are for convenience of reference only and are not
to be considered in construing this Agreement.
9.13. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.
12
If a Purchaser is in agreement with the foregoing, such Purchaser
should sign where indicated below and thereupon this letter shall become a
binding agreement between such Purchaser and the Company.
Very truly yours,
ADVANCED VIRAL RESEARCH CORP.
By:
------------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, M.D.
Title: President and Chief Executive Officer
AGREED:
-----------------------------
▇▇▇▇▇ ▇▇▇ Au
-----------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
-----------------------------
▇▇▇-▇▇▇ Law
13
EXHIBIT B
TO
SECURITIES PURCHASE AGREEMENT
DATED June 23, 1999
BETWEEN ADVANCED VIRAL RESEARCH CORP.
AND THE PURCHASERS THEREIN
Name and Address Number of Shares Number of
of Purchaser Amount of Common Stock Warrants*
------------ ------ --------------- --------
▇▇▇▇▇ ▇▇▇ Au $150,000 [Price/shr of [25% of the
c/o Pacific Trimming common stock is total number of
▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇ the average of the shares @120%
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇ closing bid prices of the per share
for the ten purchase price
consecutive trading & 25% of the
days ended on the total number of
last trading day shares @ 140%
before the closing] of the per share
purchase price]
▇▇▇▇▇▇▇ ▇▇▇▇▇▇ $250,000
PMB 456
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇-▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇-▇▇▇ Law $100,000
▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇. ▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
--------------------
*50% of such Warrants have an exercise price of [120% of per share purchase
price] per share and 50% of such warrants have an exercise price of [140% of per
share purchase price] per share.